Psoriasis Study of Health Outcomes (PSoHO) - I1F-MC-B007
Research type
Research Study
Full title
Psoriasis Study of Health Outcomes (PSoHO) – an International Observational Study of 3-Year Health Outcomes in the Biologic Treatment of Moderate-to-Severe Plaque Psoriasis
IRAS ID
251961
Contact name
Derrick Phillips
Contact email
Sponsor organisation
Lilly Deutschland GmbH
Clinicaltrials.gov Identifier
EUPAS24207, EU PAS Register
Duration of Study in the UK
4 years, 6 months, 1 days
Research summary
This study is a 36-month prospective, multi-center, international, non-interventional cohort study reflecting treatment within real-world settings of patients with moderate-to-severe plaque psoriasis who initiate their first biologic or are switched to a new biologic therapy (including biosimilars). The study will have a 24-month enrollment and a 36-month follow-up period.
Data collection will occur at baseline, first postbaseline visit (suggested window of observation: 12±4 weeks following initiation of or switch to a new biologic), 6 months postbaseline and then at 6 months visits until study completion. Subjects who discontinue biological treatment will remain in the study.
Countries participating in this study may include (but is not restricted to) France, Spain, Italy,Germany, the United Kingdom, Sweden, Netherlands, Romania, Australia, Korea, Colombia, Argentina, Mexico, Saudi Arabia, Denmark, Poland, Hungary, Canada, Brazil, Taiwan, Portugal,Israel, and United Arab Emirates.REC name
North West - Liverpool Central Research Ethics Committee
REC reference
18/NW/0736
Date of REC Opinion
25 Oct 2018
REC opinion
Favourable Opinion